BioCentury
ARTICLE | Company News

Ethicor Pharma, RXi Pharmaceuticals sales and marketing update

November 25, 2013 8:00 AM UTC

RXi granted Ethicor distribution rights to RXI-109 in the EU, with the possibility to extend to other regions, excluding North America, prior to and until the registration of the product in the countries covered by the deal. Under the European medicines legislation, Ethicor will be able to supply RXI-109 prior to regulatory approval as a "special," which may be requested by an authorized healthcare professional to meet the special needs of an individual patient under their direct responsibility. Specials cannot be actively promoted to healthcare professionals. Gross profits will be shared between the partners, and once RXI-109 is approved in a given country, the marketing rights to the approved product in that country revert back to RXi. ...